All blog posts
Total 24 results for
Showing 12 out of 24 results
29 十月 2025
"Pay-for-delay" continued: Court of Justice rules on appeal in Teva-Cephalon
14 八月 2025
China’s First Unwinding Order: SAMR Blocks Completed Below-Threshold Pharma Deal
01 十一月 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
03 十月 2024
How will the European Union develop over the next five years? Using Treaty Powers to promote Competitiveness and Security
29 七月 2024
Commission investigation into anticompetitive disparagement ends with commitments
04 七月 2024
Insights from the latest "pay-for-delay" CJEU judgments: fines on Servier and generics drug manufacturers largely upheld (but not over yet)
24 六月 2024
Overview of EU regulatory and competition law in the Pharma sector
19 二月 2024
Five Years of Activity in a Priority Sector: The European Commission's Report on Competition Enforcement in the Pharmaceutical Sector (2018-2022)
06 十二月 2023
Competition law and biosimilars: Time for a new approach or not yet?
23 十一月 2023
CMA issues guidance permitting drugs companies to work together on Combination Therapies
31 十月 2023
Another chapter in the "pay for delay" saga: General Court rules on the Teva-Cephalon settlement agreement
15 八月 2023
CAT upholds CMA excessive pricing decision in liothyronine tablets case
Showing 12 out of 24 results
View moreKey contacts
Kyriakos Fountoukakos
Managing Partner, Competition/Antitrust, Regulation and Trade, Brussels
Veronica Roberts
Partner, Head of Competition/Antitrust, Regulation and Trade, UK, London
Linda Evans
Partner, Head of Competition/Antitrust, Regulation and Trade, Australia, Sydney
Adelaide Luke
Partner, Head of Competition, Asia, Hong Kong
Jean Meijer
Managing Partner, Johannesburg Office, Johannesburg and Africa Group
Kristien Geeurickx
Knowledge Counsel, London